# A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

> **NCT07416695** · PHASE1 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 138 (estimated)

## Conditions studied

- SCLC
- NEC

## Interventions

- **DRUG:** HLX3901

## Key facts

- **NCT ID:** NCT07416695
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2028-05-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416695, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07416695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*